𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Effects of cimetidine on pharmacokinetics and pharmacodynamics of losartan, an AT1-selective non-peptide angiotensin II receptor antagonist

✍ Scribed by M. R. Goldberg; M. W. Lo; T. E. Bradstreet; M. A. Ritter; P. Högland

Publisher
Springer
Year
1995
Tongue
English
Weight
512 KB
Volume
49
Category
Article
ISSN
0031-6970

No coin nor oath required. For personal study only.

✦ Synopsis

This was a 2-period randomized, crossover study in 8 healthy males to determine the effects of cimetidine (400 mg q.i.d. for 6 days) on the pharmacokinetics and pharmacodynamic effects of the angiotensin II receptor antagonist, losartan (100 mg). Cimetidine increased the AUC for losartan 18% without affecting the AUC for E-3174, the active metabolite of losartan. The increase in plasma renin activity following losartan was not affected by cimetidine (maximum mean increases 12.6 and 12.1 ng Ang I.ml-1.h-1 without and with cimetidine, respectively). These results indicate that cimetidine does not appear to alter the pharmacokinetics or pharmacodynamics of losartan to a clinically significant extent.

📜 SIMILAR VOLUMES

Effect of losartan, an Angiotensin II re
Effect of losartan, an Angiotensin II receptor antagonist, on portal pressure in cirrhosis
✍ Arved Winfried Schneider; Johann Friedrich Kalk; Christian Peter Klein 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 163 KB 👁 1 views

Administration of angiotensin II causes an increase in portal pressure, and plasma concentration of angiotensin II is elevated in patients with cirrhosis, suggesting that angiotensin II may be involved in the pathogenesis of portal hypertension in cirrhosis. We evaluated the effect of the orally act

The pharmacokinetics and metabolism of D
The pharmacokinetics and metabolism of DuP 532, a non-peptide angiotensin II receptor antagonist, in rats and dogs
✍ Y. N. Wong; K. A. Holm; D. L. Burcham; S.-M. Huang; C. Y. Quon 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 481 KB 👁 1 views

DuP 532, 2-propy1-4-pentafluoroethyl-l-[ [2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methylJ imidazole-5-carboxylic acid, is an orally active, non-peptide angiotensin I1 (AII) receptor antagonist. DuP 532 is more potent and longer acting than losartan, another A11 receptor antagonist currently undergoing ph